LTGO logo

LTGO Latigo Biotherapeutics Inc.

NASDAQ · Medical - Pharmaceuticals · Healthcare

$19.49
-0.57 (-2.84%)

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered…

Market Cap: $1.17Bwww.latigobio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 13Aug 13

Quote

Day Range
$18.46 – $20.10
52-Week Range
$17.22 – $22.47
Volume
$303.6K
Market Cap
$1.17B
50-Day Avg
$19.04
200-Day Avg
$19.04
Prev Close
$20.06
Open
$20.01

Valuation & Ratios

P/E Ratio
EPS
P/B Ratio
P/S Ratio
Debt/Equity
Current Ratio
Dividend Yield
Gross Margin

Returns & Efficiency

Return on Equity
Return on Assets
FCF Yield
EV/EBITDA

Social Signal Score

50
5d
50
1 mentions
30d
50
1 mentions
60d
50
1 mentions
90d
50
1 mentions
news: 1

Valuation

LTGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • News247wallst.com·2d ago·Neutral

    Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about.

    View source ↗